FOLH1 and neoplasm: Despite the fact that the preclinical evaluation revealed that 68Ga-PSMA-10 was superior to 68Ga-PSMA-11 in terms of binding affinity and tumor to background ratios (IC50 = 3.9 ± 1.8 nM with a target to non-target ratio of 26.5 at 1 h p.i. as compared to a value of 9.2 for the monomer at the same time point), most of the clinical studies, so far, have been conducted using 68Ga-PSMA-11.